Security
Latigo Biotherapeutics, Inc. Common Stock · LTGO
LTGONASDAQCommon stockCurrentCIK 2056611Updated Nov 9, 2026
LTGO price & chart
Loading TradingView…
NASDAQ:LTGO on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Pain represents one of the largest and most pervasive therapeutic markets in the United States, driving an estimated 250 million prescriptions annually across acute and chronic settings; however, a continued reliance on opioids has contributed to a persistent public health crisis with significant societal and economic costs. Our two most advanced candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. We are also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches. Beyond Nav1.8, we plan to explore other ion channel targets involved in pain transmission that offer complementary mechanisms of action, enabling potential use in multi-modal treatment to enhance pain relief or address diverse pain etiologies. Pain is heterogeneous and can be experienced in a chronic or acute manner, within both musculoskeletal and neuropathic pain. Our initial development efforts are focused on musc…
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A - filed by AI Biotechnology LLC regarding Latigo Biotherapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 2.02, 5.02, 9.01
SCHEDULE 13G - filed by Westlake BioPartners Fund I, L.P. regarding Latigo Biotherapeutics, Inc.
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by AI Biotechnology LLC regarding Latigo Biotherapeutics, Inc.
SCHEDULE 13D - filed by Foresite Capital Fund VI LP regarding Latigo Biotherapeutics, Inc.
SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding Latigo Biotherapeutics, Inc.
SCHEDULE 13G - filed by Deep Track Capital, LP regarding Latigo Biotherapeutics, Inc.
Offerings
Registration 333-297518
- Gross proceeds
- 345600000.0
- Net proceeds
- 321408000.0
- Deal price
- 18.0
- Shares
- 19200000
- Offering price
- $18.00
- Ticker
- LTGO
Underwriters: Participants, Foresite Capital Fund VI, L.P.(1), Westlake BioPartners Fund II, L.P.(3)
Registration 333-298083
Filing attachments
ltgo-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as Percocet) as opioid comparator arm to the Phase 3 bunionectomy trial Phase 2 trial of LTG-321 for the treatment of chronic pain is currently ongoing; Expect to report …
Read attachment ↗ltgo-ex99_1.htm · 8-K · 2026-09-03
EX-99.1 2 ltgo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) …
Read attachment ↗tm2623428d1_ex99-1.htm · SCHEDULE 13D · 2026-08-17
Exhibit A The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Latigo Biotherapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: August 17, 2026 FORESITE CAPITAL FUND VI LP By: Foresite Capital Management VI, LLC Its: General Partner By: …
Read attachment ↗d38775dex107.htm · S-1/A · 2026-08-03
Exhibit 10.7 L ATIGO B IOTHERAPEUTICS, I NC. N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY A DOPTED : J UNE 17, 2026 Each member of the Board of Directors (the “Board”) of Latigo Biotherapeutics, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service u…
Read attachment ↗d38775dex41.htm · S-1/A · 2026-08-03
Exhibit 4.1 INCORPORATED UNDER THE CUSIP 517954 10 3 LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: COUNTERSIGNED is the record holder of AND EQUINITI FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF LATIGO BIOTHERAPEUTICS, INC. TRUST transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly REGISTERED: endorsed. This Certificate is n…
Read attachment ↗d38775dex42.htm · S-1 · 2026-07-17
Exhibit 4.2 Execution Version LATIGO BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT T HIS A MENDED A ND R ESTATED I NVESTORS ’ R IGHTS A GREEMENT (this “Agreement”), is made as of January 28, 2025, by and among Latigo Biotherapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS W HEREAS, certain of the Investors (the “Existing Investors”) ho…
Read attachment ↗